Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status
| Autor: | Hajime Yamakage, Noriko Satoh-Asahara, Yousuke Sasaki, Akira Shimatsu, Akihiro Himeno, Takeshi Usui, Kazuya Muranaka, Shigeto Uchiyama, Asami Inaguma, Tomomi Ueno, Mayu Tochiya |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Phytoestrogens Overweight chemistry.chemical_compound Endocrinology Asian People Internal medicine Medicine Humans Obesity education Glycated Hemoglobin Metabolic Syndrome education.field_of_study business.industry food and beverages Equol Cholesterol LDL medicine.disease Crossover study chemistry Dietary Supplements (S)-Equol Female Metabolic syndrome medicine.symptom business Body mass index |
| Zdroj: | Clinical endocrinology. 78(3) |
| ISSN: | 1365-2265 |
| Popis: | SummaryObjectives Epidemiologic studies indicate that soy intake has an important role in the prevention of age-related health problems. Daidzein, the principal isoflavone contained in soy, is converted to S-equol by the intestinal bacteria. Not all individuals, however, can produce S-equol, which is considered the most biologically active metabolite. We studied the effects of a natural S-equol supplement on metabolic parameters associated with overweight or obesity and metabolic syndrome. Methods The study was a randomized, double-blinded, placebo-controlled, crossover design with no washout period. All subjects were considered overweight or obese if they had a body mass index ≧25 kg/m2. Placebo or natural S-equol tablets containing 10 mg S-equol were orally ingested each day for 12 weeks. A total of 54 Japanese overweight or obese outpatients were enrolled. The equol phenotype was determined, and various metabolic parameters, including cardio-ankle vascular index (CAVI), were measured. Results Equol non-producers comprised 67·9% of the overweight or obese subjects. The ratio of equol non-producers in this overweight or obese subject group was higher than the previously reported ratio of equol non-producers (approximately 50%) in the general population. Compared with the placebo group, intervention with natural S-equol led to a significant decrease in HbA1c, serum low-density lipoprotein cholesterol (LDL-C) levels and CAVI score. Furthermore, the effect was more prominent in the subgroup of female equol non-producers. Conclusion The ratio of equol non-producers in overweight or obese populations might be higher than generally reported. Natural S-equol might have a role in glycaemic control and in the prevention of cardiovascular disease by its effects to lower LDL-C levels and CAVI scores in overweight or obese individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text